全文获取类型
收费全文 | 439篇 |
免费 | 23篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 13篇 |
妇产科学 | 5篇 |
基础医学 | 44篇 |
口腔科学 | 24篇 |
临床医学 | 56篇 |
内科学 | 120篇 |
皮肤病学 | 22篇 |
神经病学 | 7篇 |
特种医学 | 75篇 |
外科学 | 20篇 |
综合类 | 19篇 |
预防医学 | 33篇 |
眼科学 | 1篇 |
药学 | 21篇 |
中国医学 | 1篇 |
肿瘤学 | 12篇 |
出版年
2023年 | 4篇 |
2022年 | 4篇 |
2021年 | 5篇 |
2020年 | 5篇 |
2019年 | 5篇 |
2018年 | 7篇 |
2017年 | 5篇 |
2016年 | 11篇 |
2015年 | 7篇 |
2014年 | 9篇 |
2013年 | 17篇 |
2012年 | 4篇 |
2011年 | 8篇 |
2010年 | 18篇 |
2009年 | 25篇 |
2008年 | 7篇 |
2007年 | 20篇 |
2006年 | 6篇 |
2005年 | 4篇 |
2004年 | 5篇 |
2003年 | 5篇 |
2002年 | 3篇 |
2001年 | 8篇 |
1999年 | 6篇 |
1998年 | 30篇 |
1997年 | 30篇 |
1996年 | 30篇 |
1995年 | 25篇 |
1994年 | 17篇 |
1993年 | 19篇 |
1992年 | 7篇 |
1991年 | 3篇 |
1990年 | 11篇 |
1989年 | 12篇 |
1988年 | 15篇 |
1987年 | 19篇 |
1986年 | 6篇 |
1985年 | 4篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1977年 | 7篇 |
1976年 | 4篇 |
1975年 | 3篇 |
1970年 | 2篇 |
1912年 | 3篇 |
1911年 | 2篇 |
1910年 | 2篇 |
1909年 | 2篇 |
排序方式: 共有474条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Studies of proteins that inhibit tissue factor activity have generally been conducted using either an extracted tissue homogenate ("thromboplastin") or tissue factor protein reconstituted into phospholipid vesicles rather than with tissue factor expressed in cell membranes (its physiological environment). In the present study, a human fibroblast cell strain was used to evaluate the effects of lipoprotein associated coagulation inhibitor (LACI), placental anticoagulant protein (PAP), and apolipoprotein A-II (apo A-II) on human tissue factor in cell membranes. LACI was tested from 7.8 to 500 pmol/L on fibroblasts cultured at cell densities ranging from 3,500 to 9,925 cells/well, and caused a progressive inhibition of tissue factor activity. PAP was tested from 3.9 nmol/L to 1 mumol/L at cell densities ranging from 4,500 to 15,400 cells/well and caused up to 83% inhibition of tissue factor activity. Inhibition by these proteins appeared to be influenced by cell density as well as whether the cells were intact or disrupted. Apo A-II, up to 1 mumol/L, did not inhibit the tissue factor activity of intact or disrupted fibroblasts at any cell density examined even though it did inhibit the activity of tissue factor in phospholipid vesicles. Of these inhibitors of tissue factor-dependent activation of factor X, LACI was the most effective in suppressing the generation of factor Xa activity. The effects obtained with apo A-II are clearly dependent on the nature of the tissue factor preparation with which it is tested. The disparity between the inhibitory effect of apo A-II on the activity of tissue factor reconstituted into lipid vesicles and the absence of effect on the activity of tissue factor remaining in cell membranes serves to reemphasize the necessity of reexamining results obtained with model systems using as nearly physiological reagents as possible. 相似文献
5.
Myosin VIIA gene: heterogeneity of the mutations responsible for Usher syndrome type IB 总被引:8,自引:1,他引:8
Levy G; Levi-Acobas F; Blanchard S; Gerber S; Larget-Piet D; Chenal V; Liu XZ; Newton V; Steel KP; Brown SD; Munnich A; Kaplan J; Petit C; Weil D 《Human molecular genetics》1997,6(1):111-116
Usher syndrome is recognized as the most frequent cause of hereditary
deaf-blindness. Usher syndrome type I (USH1), the most severe form of the
disease, is characterized by profound congenital sensorineural deafness,
constant vestibular dysfunction, and retinitis pigmentosa of prepubertal
onset. This form is genetically heterogeneous and five loci (USH1A-E) have
been mapped thusfar. However, only the gene responsible for USH1 B (which
accounts for approximately 75% of USH1 cases) has been characterized. It
encodes a long-tailed unconventional myosin, myosin VIIA, with a predicted
2215 amino acid sequence. Primers covering the complete myosin VIIA coding
sequence as well as the 3' non coding sequence were designed, allowing
direct sequence analysis of each of the 48 coding exons and flanking splice
sites in seven patients affected by USH1. Four novel mutations were thereby
identified. The possibility should now be considered of a sequence-based
prenatal diagnosis in some of the families affected by this very severe
form of Usher syndrome.
相似文献
6.
7.
8.
Devasia RA Varma JK Whichard J Gettner S Cronquist AB Hurd S Segler S Smith K Hoefer D Shiferaw B Angulo FJ Jones TF 《Microbial drug resistance (Larchmont, N.Y.)》2005,11(4):371-377
Multidrug-resistant Salmonella Newport with decreased susceptibility to ceftriaxone (MDR-AmpC) is becoming increasingly common in its food animal reservoirs and in humans. Few data exist on rates of antimicrobial use or differences in clinical outcomes in persons infected with MDR-AmpC or other Salmonella strains. We conducted a case-comparison analysis of data from a multistate population-based case-control study to identify antimicrobial treatment choices and differences in clinical outcomes in those infected with MDRAmpC compared to pansusceptible S. Newport. Of isolates from 215 laboratory-confirmed S. Newport cases, 54 (25%) were MDR-AmpC, 146 (68%) were pansusceptible, and 15 (7%) had other resistance patterns; 146 (68%) patients with S. Newport were treated with antimicrobial agents and 66 (33%) were hospitalized. Over two-thirds of cases at low-risk for serious complications received antimicrobial therapy, most commonly with fluoroquinolones, to which this strain was susceptible. There were no significant differences in symptoms, hospitalization, duration of illness, or other outcomes between the persons infected with MDR-AmpC and pansusceptible S. Newport. Although currently prevalent MDR-AmpC S. Newport strains remains susceptible to the antimicrobial most commonly prescribed for it, continued efforts to reduce unnecessary use of antimicrobial agents in food animals and humans are critical to prevent further development of resistance to quinolones and cephalosporins, which is likely to lead to substantial adverse outcomes. 相似文献
9.
10.
Evolutionary silencing of the human elastase I gene (ELA1) 总被引:6,自引:0,他引:6